SAUL Trial Data: Real World Experience of Atezolizumab in Carcinomas of the Urinary Tract- Cora Sternberg

Cora Sternberg, MD and Alicia Morgans, MD discuss the SAUL (A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract) trial data which represents the "real world" experience with atezolizumab for the treatment of carcinomas of the urinary tract.  The SAUL study enrolled patients that typically would be excluded from clinical trials including those patients with poor renal function, patients on dialysis, patients with immune disorders and poor performance status.  The data demonstrates that these patients can be safely treated with immune check point blockade, specifically with atezolizumab.  Safety was similar to what was seen in the registration studies.  Efficacy was also similar in this real world population with the exception of those patients who were performance status 2, who did a bit worse than the overall population.  This study demonstrates that patients with poor renal function and immune disorders are able to safely receive atezolizumab for carcinomas of the urinary tract. 
Biographies:

Cora Sternberg MD, FACP Clinical Director of the Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, Former Chief of the Department of Medical Oncology at the San Camillo-Forlanini Hospital in Rome, Italy

Alicia Morgans, MD, MPH, Associate Professor of Medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.

Related Content:

NCT02928406 An Open Label, Single Arm, Multicenter, Safety Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract

Primary Results from SAUL: A Prospective, Multinational Single-Arm Study of Atezolizumab for Locally Advanced or Metastatic Urothelial Carcinoma of the Urinary Tract

Abstract: Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract.
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe